Alnylam Pharmaceuticals

ALNY

Market cap $45.3B

Investors need to pay close attention to ALNY stock based on the movements in the options market lately.

With Hologic due to get acquired, Marvell, Alnylam and Veeva are among the eligible replacements, according to an analyst.

Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) portfolio presented at the American College of Cardiology's Annual Scientific Session and Expo (ACC.26), reinforcing the potential of RNAi to deliver fundamentally differentiated, effective, and durable impact for patients living with cardiovascular disease (CVD). New data continue to support the use.

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise Transcript

SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to accelerate early identification and standardize diagnostic evaluation of patients with cardiac amyloidosis, a serious and underdiagnosed cause of heart failure. Cardiac amyloidosis is a progressive condition in which misfolded proteins deposit in the heart muscle, leading to heart failure a.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination for patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Through complementary initiatives with Viz.ai and the American Heart Association, Alnylam is advancing a comprehensive, system‑level approach to address.

ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.

Investing in equities involves accepting volatility as the cost of long-term compounding. In 15 significant systemic shocks during which Alnylam Pharmaceuticals (ALNY) was traded, the stock experienced an average drawdown of -25%.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company's website, www.alnylam.com, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. The TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA® in ATTR-CM, will highlight Alnylam'.